## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.9% in mid entry zone (3.0-6.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (3.5%) confirms momentum alignment. Strong momentum (+3.9% 5-day acceleration). Outperforming sector by 3.3%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($230.40)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Iqvia stock hits 52-week high at 234.33 USD By Investing.com**
- Source: Investing.com UK | 20260105T203626 | Bullish | Relevance: 100%
- Iqvia Holdings Inc. (IQV) stock reached a 52-week high of $234.33, reflecting a 14.17% return over the past year and a 37.22% surge in six months, with a "GOOD" financial health rating and a market cap of $39.87 billion. Despite trading near its peak, InvestingPro's Fair Value analysis suggests the stock is slightly undervalued, with analysts setting targets as high as $273. Recent strategic moves include refinancing loans, a partnership with Amazon Web Services for AI-powered clinical trial automation, and the appointment of Nobel laureate Dr. William G. Kaelin Jr. to its board.

**2. The 24% return delivered to IQVIA Holdings' (NYSE:IQV) shareholders actually lagged YoY earnings growth**
- Source: Yahoo Finance | 20260106T120806 | Somewhat-Bearish | Relevance: 100%
- IQVIA Holdings Inc. (NYSE:IQV) saw a 24% share price increase over five years, falling short of the broader market return, despite a 16% gain in the last year. The company's impressive 52% annual compound EPS growth over five years outpaced its 4% yearly share price gain during the same period, suggesting the market is not fully recognizing its strong earnings performance. Shareholders experienced a 16% return for the year, which, while positive, still lagged the overall market.

**3. Community Trust & Investment Co. Cuts Stock Position in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20260106T095727 | Neutral | Relevance: 100%
- Community Trust & Investment Co. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% in the third quarter, now owning 108,911 shares valued at $20,687,000. Other institutions like Asset Dedication LLC and J.Safra Asset Management Corp. increased their holdings in IQVIA. Analysts have given the stock a consensus "Moderate Buy" rating with a target price of $243.19, following upgrades from firms like Jefferies Financial Group and Evercore ISI.

**4. Ações da Iqvia atingem máxima de 52 semanas a US$ 234,33**
- Source: Investing.com Brasil - Finanças, Câmbio e Investimentos | 20260106T000806 | Bullish | Relevance: 100%
- As ações da IQVIA Holdings Inc. (IQV) atingiram uma máxima de 52 semanas de US$ 234,33, refletindo um forte desempenho e confiança dos investidores. A empresa, avaliada em US$ 39,87 bilhões, tem uma saúde financeira "BOA" e tem otimizado sua estrutura financeira, além de formar uma parceria estratégica com a Amazon Web Services. Analistas como Stifel e Morgan Stanley mantêm perspectivas positivas para a IQVIA, com preços-alvo que chegam a US$ 273.

**5. Iqvia stock hits 52-week high at 234.33 USD By Investing.com**
- Source: Investing.com Canada | 20260105T211956 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) stock has reached a new 52-week high of $234.33, driven by strong market performance, with a 14.17% return over the past year and a 37.22% surge in six months. The company, which has a market cap of $39.87 billion and a "GOOD" financial health rating, is seen as slightly undervalued according to InvestingPro's Fair Value analysis. Recent strategic moves, such as refinancing existing loans and a collaboration with Amazon Web Services, along with positive analyst price target revisions, suggest continued investor confidence and growth prospects for the life sciences tools and services provider.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 18.6x stretched relative to 9% growth. Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $41.0B |
| Beta | 1.37 |
| 52W Range | $134.65 - $241.81 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 18.6 |
| Current P/E | 20.2 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.1% to 4.9% (+3.9% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 3.5% confirms short-term momentum alignment. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.11), confirming momentum. RSI overbought at 73, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.93% (CS: 84) | Strong |
| RSI_14 | 72.6 | Overbought |
| MACD Histogram | 1.11 | Bullish |
| vs SMA20 | 1.068x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.305x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $240.56
- **Stop Loss:** $230.40 (4.2% risk)
- **Target:** $255.80 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 129
- **Position Value:** $31,032.24
- **Portfolio %:** 31.03%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*